Get started
Author

Tina Laga

Observed names: T Laga, T. Laga
Institution: KU Leuven
ORCID: 0000-0002-7001-9394
Observed ORCID: 0000-0002-7001-9394
OpenAlex ID: A5070452913
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
2023 · Liselore Loverix, Ignace Vergote, et al. · European Journal of Cancer · 38
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)
2022 · Liselore Loverix, Ignace Vergote, et al. · Gynecologic Oncology · 23
MetDecode: methylation-based deconvolution of cell-free DNA for noninvasive multi-cancer typing
2024 · Antoine Passemiers, Stefania Tuveri, et al. · Bioinformatics · 13
PDF
Immunotherapy in rare ovarian cancer
2021 · Tina Laga, Ignace Vergote, et al. · Current Opinion in Oncology · 12
Positive DESKTOP and Tian Scores Systems Are Adequate to Predict Optimal (R0) Secondary Debulking Surgery in Ovarian Cancer, But a Negative Score Does Not Preclude Secondary Surgery
2018 · Tina Laga, Sandrina Lambrechts, et al. · International Journal of Gynecological Cancer · 9
Single-cell profiling in ovarian germ cell and sex cord-stromal tumours
2025 · T. Laga, AS Van Rompuy, et al. · British Journal of Cancer · 5
2022-RA-1136-ESGO A single-cell map of rare ovarian cancer
2022 · Tina Laga, Pieter Busschaert, et al. · International Journal of Gynecological Cancer · 2
PDF
Using machine learning to estimate time-to-progression in ovarian cancer based on cancer registry and administrative health data
2026 · A. Leloup, J. Verbeeck, et al. · ESMO Real World Data and Digital Oncology
‘Multi-Omics’ In Endometriosis Related Ovarian Cancer
2025 · Tina Laga, Anne-Sophie Van Rompuy, et al. · International Journal of Gynecological Cancer
PDF
14P Unravelling the immune landscape of non-epithelial ovarian cancer
2023 · T. Laga, A-S. Van Rompuy, et al. · ESMO Open
2022-RA-1473-ESGO Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in recurrent ovarian cancer – results of the Leuven HRD test
2022 · Liselore Loverix, Ignace Vergote, et al. · International Journal of Gynecological Cancer
PDF
2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer
2022 · Liselore Loverix, Rawand Salihi, et al. · International Journal of Gynecological Cancer
415 Single-cell map of the dynamic changes underlying platinum-based chemotherapy with or without bevacizumab in high-grade serous tubo-ovarian carcinoma
2021 · S Olbrecht, P Busschaert, et al. · Ovarian cancer
PDF
Works count: 13
Citation count: 102
H-index: 5
I10-index: 4
Year
Topic
Type